Top 10 medtech deals in the first half of 2026
Boston Scientific, Medtronic and Stryker were among the companies to ink deals to move into markets that are expanding quickly.
Uncategorized
Genentech culls 103 jobs, inks $490M-plus biobucks deal with Astex
With the latest round, Roche’s Genentech will have racked up nearly 450 layoffs in California over the last year amid ongoing restructuring. At the same time, the biotech is joining forces with Astex Pharmaceuticals in a deal that could surpass $490 million.
Genentech culls 103 jobs, inks $490M-plus biobucks deal with Astex Read More »
La clave de cómo nuestra galaxia sobrevivió a la era más violenta del universo
Hace unos diez mil millones de años, muchas galaxias dejaron de existir como estructuras individuales, al ser tragadas por otras galaxias mayores, o al colisionar y fusionarse con otras de masa similar. Nuestra galaxia consiguió sobrevivir como estructura mayormente individual …
La clave de cómo nuestra galaxia sobrevivió a la era más violenta del universo Read More »
Epic president to step down this summer
Sumit Rana’s departure could be a significant leadership shakeup for Epic, as the president was viewed as a potential successor to the company’s 82 year-old CEO.
Nueva especie de perro-oso del Mioceno medio
Los anficiónidos —coloquialmente conocidos como “perros-oso” (bear-dogs, en inglés)— fueron un grupo de carnívoros que prosperó en América del Norte y Eurasia durante buena parte del Cenozoico, desde el Eoceno hasta el Mioceno tardío. A …
Hair loss biotech Veradermics, up 656% since its IPO, credits the obesity boom
After debuting on the public markets with $256.3 million and raking in an additional $472 million, Veradermics has emerged as one of biotech’s biggest post-IPO standouts. CEO Reid Waldman credits the weight loss craze for establishing consumer-driven channels.
Hair loss biotech Veradermics, up 656% since its IPO, credits the obesity boom Read More »
Medicare slashes 340B payments, broadens site-neutral policies in proposed 2027 payment rule
The rule, released Thursday, builds on Trump administration’s priorities, including cutting Medicare reimbursement for drugs in the controversial 340B program and equalizing payment between sites of care.
Novartis drops up to $1.5B for ADC specialist Myricx, continuing cancer spending spree
The centerpiece of the acquisition is Myricx Bio’s novel N-myristoyltransferase inhibitor payload platform, which could help Novartis develop antibody-drug conjugates that can overcome the limitations of existing therapies.
Novartis drops up to $1.5B for ADC specialist Myricx, continuing cancer spending spree Read More »
Early-stage Scribe wants to write IPO story even as investors favor derisked portfolios
Scribe Therapeutics’ pipeline is immature, with its lead program recently greenlit for first-in-human testing. The biotech is working on CRISPR-based therapies for cardiometabolic diseases.
Early-stage Scribe wants to write IPO story even as investors favor derisked portfolios Read More »
BridgeBio touts kidney benefits for Attruby, differentiating from amyloidosis competitors
BridgeBio’s Attruby preserves kidney function in patients with transthyretin amyloidosis cardiomyopathy, an effect that is “distinct” from other drugs in this space, according to Jefferies.